GPC2 and Nijmegen breakage syndrome: Amongst the NB-specific cell surface molecules, glypican-2 (GPC2) can be considered an ideal immunotherapeutic target being overexpressed on high-risk NBs and restricted on normal childhood tissues (Figure 1).